{"id":"https://openalex.org/W4391232200","doi":"https://doi.org/10.1093/ibd/izae020.094","title":"COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US","display_name":"COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US","publication_year":2024,"publication_date":"2024-01-25","ids":{"openalex":"https://openalex.org/W4391232200","doi":"https://doi.org/10.1093/ibd/izae020.094"},"language":"en","primary_location":{"id":"doi:10.1093/ibd/izae020.094","doi":"https://doi.org/10.1093/ibd/izae020.094","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ibd/izae020.094","pdf_url":"https://academic.oup.com/ibdjournal/article-pdf/30/Supplement_1/S44/56417403/izae020.094.pdf","source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/ibdjournal/article-pdf/30/Supplement_1/S44/56417403/izae020.094.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101536050","display_name":"Xuan Wang","orcid":"https://orcid.org/0000-0003-2282-5188","observed_orcids":["https://orcid.org/0000-0003-2282-5188"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xuan Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017248751","display_name":"Lytske Jantien Bakker","orcid":"https://orcid.org/0000-0001-8583-0115","observed_orcids":["https://orcid.org/0000-0001-8583-0115"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lytske Bakker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074126560","display_name":"Navneet Upadhyay","orcid":"https://orcid.org/0000-0003-3776-9596","observed_orcids":["https://orcid.org/0000-0003-3776-9596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Navneet Upadhyay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063199784","display_name":"Susanne Hartz","orcid":"https://orcid.org/0000-0001-8475-0260","observed_orcids":["https://orcid.org/0000-0001-8475-0260"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susanne Hartz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108542558","display_name":"M. Treur","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maarten Treur","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5015901006","display_name":"Axel Svedbom","orcid":"https://orcid.org/0000-0003-2596-1679","observed_orcids":["https://orcid.org/0000-0003-2596-1679"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Axel Svedbom","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4055,"currency":"USD","value_usd":4055},"apc_paid":null,"fwci":0.5128,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.62057712,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":96},"biblio":{"volume":"30","issue":"Supplement_1","first_page":"S44","last_page":"S45"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9359999895095825,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9359999895095825,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0560000017285347,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13569","display_name":"Microscopic Colitis","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mirikizumab","display_name":"mirikizumab","score":0.9750000238418579},{"id":"https://openalex.org/keywords/ustekinumab","display_name":"ustekinumab","score":1.0}],"concepts":[{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.9503117799758911},{"id":"https://openalex.org/C2780479503","wikidata":"https://www.wikidata.org/wiki/Q1477","display_name":"Ulcerative colitis","level":3,"score":0.9324861764907837},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7855673432350159},{"id":"https://openalex.org/C2776207728","wikidata":"https://www.wikidata.org/wiki/Q7918002","display_name":"Vedolizumab","level":4,"score":0.6512437462806702},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4891946315765381},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4870870113372803},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.17876720428466797},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.13745272159576416}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/ibd/izae020.094","doi":"https://doi.org/10.1093/ibd/izae020.094","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ibd/izae020.094","pdf_url":"https://academic.oup.com/ibdjournal/article-pdf/30/Supplement_1/S44/56417403/izae020.094.pdf","source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/ibd/izae020.094","doi":"https://doi.org/10.1093/ibd/izae020.094","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ibd/izae020.094","pdf_url":"https://academic.oup.com/ibdjournal/article-pdf/30/Supplement_1/S44/56417403/izae020.094.pdf","source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4391232200.pdf","grobid_xml":"https://content.openalex.org/works/W4391232200.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391232209","https://openalex.org/W6921064946","https://openalex.org/W4391218341","https://openalex.org/W7165394877","https://openalex.org/W7125452702","https://openalex.org/W4403725689","https://openalex.org/W7125159901","https://openalex.org/W4400192886","https://openalex.org/W7162014997","https://openalex.org/W4408036330"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND":[1],"Mirikizumab,":[2],"an":[3,44,101,353],"interleukin":[4],"(IL)-23p19":[5],"inhibitor,":[6],"demonstrated":[7,394],"efficacy":[8,322],"compared":[9,69,292,375,402],"to":[10,20,29,70,80,127,132,148,175,293,341,376,385,403,406],"placebo":[11],"in":[12,15,41,51,72,97,134,144,247,279,378,408],"clinical":[13,145],"trials":[14],"adult":[16],"patients":[17,76,170,382],"with":[18,78,89,383,391],"moderately":[19,79,384],"severely":[21,81,386],"active":[22,82,387],"ulcerative":[23],"colitis":[24],"(UC).":[25],"Mirikizumab":[26,277],"is":[27,47,189,336],"expected":[28],"receive":[30],"approval":[31],"from":[32,191,219,233],"the":[33,48,64,73,154,160,176,208,266,321,328,371,379],"United":[34],"States":[35],"(US)":[36],"Food":[37],"and":[38,115,165,184,212,223,253,272,285,309,327,358],"Drug":[39],"Administration":[40],"2023.":[42],"Ustekinumab,":[43],"IL12/23":[45],"antagonist,":[46],"preferred":[49],"option":[50],"advanced":[52],"therapy":[53],"(AT;":[54],"biologics,":[55],"novel":[56],"targeted":[57],"systemics)":[58],"experienced":[59],"patients.":[60],"OBJECTIVES":[61],"To":[62],"evaluate":[63],"cost":[65,305],"effectiveness":[66],"of":[67,137,141,210,268,304,319,323,330,344,373],"mirikizumab":[68,314,324,335,361,374,397],"ustekinumab":[71,294,357,377],"US":[74,197,235,249,380],"among":[75],"diagnosed":[77],"UC":[83,388],"who":[84,171],"have":[85],"been":[86],"previously":[87,389],"treated":[88,390],"AT.":[90,392],"METHODS":[91],"A":[92],"Markov":[93],"model":[94],"was":[95,350],"developed":[96],"MS":[98],"Excel,":[99],"comprising":[100,182],"AT":[102,108,161],"layer,":[103,109,114,181],"a":[104,110,116,138,220,234,239,339],"second":[105],"line":[106],"(2L)":[107],"conventional":[111],"treatment":[112],"(CT)":[113],"surgery":[117,180,183],"layer.":[118],"Following":[119],"initial":[120],"induction":[121,133,326],"(2-week":[122],"cycle":[123,158],"length),":[124,159],"responders":[125],"transition":[126,131,174,213],"maintenance,":[128],"while":[129],"non-responders":[130],"2L,":[135,177],"consisting":[136],"weighted":[139],"mix":[140],"ATs":[142],"used":[143],"practice":[146],"according":[147],"market":[149],"shares,":[150],"or":[151,179],"CT.":[152],"During":[153],"maintenance":[155,216],"phase":[156],"(12-week":[157],"layers":[162],"include":[163],"remission":[164],"non-remission":[166,205],"response":[167,173,206],"health":[168,186,193,228],"states;":[169],"lose":[172],"CT":[178],"post-surgery":[185],"states.":[187],"Death":[188],"possible":[190],"all":[192],"states,":[194],"as":[195,226],"per":[196,347],"2020":[198],"national":[199],"life":[200],"tables.":[201],"Probabilities":[202],"for":[203,313,356,360,381],"remission,":[204],"at":[207,257,295,325,338],"end":[209],"induction,":[211],"probabilities":[214],"during":[215],"were":[217,227,255,261,315],"derived":[218],"network":[221],"meta-analysis":[222],"published":[224],"literature,":[225],"state":[229],"utilities.":[230],"The":[231,332,366],"analysis":[232],"payer's":[236],"perspective":[237],"over":[238],"lifetime":[240],"horizon":[241],"considered":[242,400],"only":[243],"direct":[244],"medical":[245],"costs":[246,282],"2023":[248],"dollars":[250],"(USD).":[251],"Costs":[252],"outcomes":[254],"discounted":[256],"3%.":[258],"Sensitivity":[259],"analyses":[260,264,367],"performed;":[262],"scenario":[263],"explored":[265],"impact":[267],"re-induction,":[269],"dose":[270,355],"escalation,":[271],"including":[273],"societal":[274],"costs.":[275],"RESULTS":[276],"resulted":[278],"lower":[280],"total":[281],"(USD":[283,298,307],"1,232,582)":[284],"more":[286],"quality-adjusted":[287],"life-years":[288],"(QALYs)":[289],"(10.352)":[290],"when":[291],"standard":[296],"doses":[297],"1,279,620;":[299],"10.247":[300],"QALYs).":[301],"Key":[302],"drivers":[303],"savings":[306],"-47,038)":[308],"higher":[310],"QALYs":[311],"(0.105)":[312],"assumptions":[316],"on":[317],"loss":[318],"response,":[320],"price":[329],"mirikizumab.":[331],"probability":[333],"that":[334,395],"cost-effective":[337,401],"willingness":[340],"pay":[342],"threshold":[343],"USD":[345],"100,000":[346],"QALY":[348],"gained":[349],"74.9%.":[351],"Adopting":[352],"escalated":[354],"re-induction":[359],"considerably":[362],"increased":[363],"savings.":[364],"CONCLUSIONS":[365],"provided":[368],"insights":[369],"into":[370],"cost-effectiveness":[372],"Results":[393],"adopting":[396],"can":[398],"be":[399],"ustekinumab,":[404],"contributing":[405],"decision-making":[407],"healthcare":[409],"management.":[410]},"counts_by_year":[{"year":2026,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2024-01-26T00:00:00"}